Checkpoint Therapeutics Announces Cosibelimab Longer-Term Data Showing Increases In Complete Response Rates In Advanced Cutaneous Squamous Cell Carcinoma
Portfolio Pulse from Bill Haddad
Checkpoint Therapeutics has announced longer-term data showing increases in complete response rates for its drug, Cosibelimab, in advanced cutaneous squamous cell carcinoma. The drug demonstrated a 55% objective response rate and a 23% complete response rate in locally advanced cSCC, and a 50% objective response rate and a 13% complete response rate in metastatic cSCC. The drug continues to show a favorable safety profile and its Biologics License Application is currently under review by the U.S. FDA, with a PDUFA goal date of January 3, 2024.

July 27, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Checkpoint Therapeutics' drug, Cosibelimab, shows promising results in advanced cSCC. The drug's Biologics License Application is currently under FDA review.
The positive results from the longer-term data of Cosibelimab could potentially boost investor confidence in Checkpoint Therapeutics. The ongoing FDA review of the drug's Biologics License Application also adds to the potential positive impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100